Bicycle Therapeutics plc (FRA:50BA)
Germany
· Delayed Price · Currency is EUR 5.90
+0.20 (3.51%)
At close: Dec 4, 2025
Bicycle Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Revenue | 28.34 | 35.28 | 26.98 | 14.46 | 11.7 | 10.39 | Upgrade
|
| Revenue Growth (YoY) | -23.20% | 30.76% | 86.52% | 23.65% | 12.58% | -24.72% | Upgrade
|
| Cost of Revenue | 239.24 | 172.97 | 156.5 | 81.61 | 44.88 | 33.15 | Upgrade
|
| Gross Profit | -210.9 | -137.69 | -129.52 | -67.15 | -33.18 | -22.76 | Upgrade
|
| Selling, General & Admin | 79.12 | 72.18 | 60.43 | 49.51 | 32.44 | 29.2 | Upgrade
|
| Operating Expenses | 79.12 | 72.18 | 60.43 | 49.51 | 32.44 | 29.2 | Upgrade
|
| Operating Income | -290.02 | -209.87 | -189.95 | -116.65 | -65.62 | -51.96 | Upgrade
|
| Interest Expense | -0.2 | -1.73 | -3.26 | -3.34 | -2.98 | -0.46 | Upgrade
|
| Interest & Investment Income | 32.89 | 34.28 | 14 | 5.76 | 0.12 | 0.68 | Upgrade
|
| EBT Excluding Unusual Items | -257.33 | -177.32 | -179.21 | -114.24 | -68.48 | -51.73 | Upgrade
|
| Other Unusual Items | 4.48 | 3.52 | - | - | - | - | Upgrade
|
| Pretax Income | -252.86 | -173.8 | -179.21 | -114.24 | -68.48 | -51.73 | Upgrade
|
| Income Tax Expense | -2.2 | -4.77 | 1.46 | -1.52 | -1.66 | -0.72 | Upgrade
|
| Net Income | -250.66 | -169.03 | -180.66 | -112.72 | -66.82 | -51.01 | Upgrade
|
| Net Income to Common | -250.66 | -169.03 | -180.66 | -112.72 | -66.82 | -51.01 | Upgrade
|
| Shares Outstanding (Basic) | 69 | 58 | 36 | 30 | 25 | 19 | Upgrade
|
| Shares Outstanding (Diluted) | 69 | 58 | 36 | 30 | 25 | 19 | Upgrade
|
| Shares Change (YoY) | 34.28% | 63.54% | 20.00% | 18.35% | 30.90% | 73.34% | Upgrade
|
| EPS (Basic) | -3.62 | -2.90 | -5.08 | -3.80 | -2.67 | -2.66 | Upgrade
|
| EPS (Diluted) | -3.62 | -2.90 | -5.08 | -3.80 | -2.67 | -2.66 | Upgrade
|
| Free Cash Flow | -241.87 | -165.96 | -63.56 | -105.1 | -16.82 | -18.99 | Upgrade
|
| Free Cash Flow Per Share | -3.49 | -2.85 | -1.79 | -3.54 | -0.67 | -0.99 | Upgrade
|
| Gross Margin | - | - | - | - | -283.69% | -219.05% | Upgrade
|
| Operating Margin | -1023.39% | -594.96% | -704.13% | -806.56% | -560.98% | -500.10% | Upgrade
|
| Profit Margin | -884.51% | -479.18% | -669.72% | -779.35% | -571.25% | -490.95% | Upgrade
|
| Free Cash Flow Margin | -853.49% | -470.47% | -235.61% | -726.67% | -143.83% | -182.76% | Upgrade
|
| EBITDA | -283.23 | -202.7 | -183.4 | -112.96 | -64.21 | -50.68 | Upgrade
|
| D&A For EBITDA | 6.79 | 7.17 | 6.55 | 3.69 | 1.41 | 1.28 | Upgrade
|
| EBIT | -290.02 | -209.87 | -189.95 | -116.65 | -65.62 | -51.96 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.